AU2013230112A1 - Identification of channelrhodopsin-2 (Chop2) mutations and methods of use - Google Patents

Identification of channelrhodopsin-2 (Chop2) mutations and methods of use Download PDF

Info

Publication number
AU2013230112A1
AU2013230112A1 AU2013230112A AU2013230112A AU2013230112A1 AU 2013230112 A1 AU2013230112 A1 AU 2013230112A1 AU 2013230112 A AU2013230112 A AU 2013230112A AU 2013230112 A AU2013230112 A AU 2013230112A AU 2013230112 A1 AU2013230112 A1 AU 2013230112A1
Authority
AU
Australia
Prior art keywords
molecule
amino acid
cell
polypeptide molecule
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013230112A
Other languages
English (en)
Inventor
Zhuo-Hua Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of AU2013230112A1 publication Critical patent/AU2013230112A1/en
Priority to AU2017239601A priority Critical patent/AU2017239601B2/en
Priority to AU2019216638A priority patent/AU2019216638B2/en
Priority to AU2021245195A priority patent/AU2021245195B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2013230112A 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (Chop2) mutations and methods of use Abandoned AU2013230112A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2017239601A AU2017239601B2 (en) 2012-03-05 2017-10-06 Identification of Channelopsin-2 (Chop2) mutations and methods of use
AU2019216638A AU2019216638B2 (en) 2012-03-05 2019-08-14 Identification of Channelopsin-2 (Chop2) mutations and methods of use
AU2021245195A AU2021245195B2 (en) 2012-03-05 2021-10-07 Identification of Channelopsin-2 (Chop2) mutations and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606663P 2012-03-05 2012-03-05
US61/606,663 2012-03-05
PCT/US2013/029171 WO2013134295A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017239601A Division AU2017239601B2 (en) 2012-03-05 2017-10-06 Identification of Channelopsin-2 (Chop2) mutations and methods of use

Publications (1)

Publication Number Publication Date
AU2013230112A1 true AU2013230112A1 (en) 2014-09-25

Family

ID=47892055

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013230112A Abandoned AU2013230112A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (Chop2) mutations and methods of use
AU2017239601A Active AU2017239601B2 (en) 2012-03-05 2017-10-06 Identification of Channelopsin-2 (Chop2) mutations and methods of use
AU2019216638A Active AU2019216638B2 (en) 2012-03-05 2019-08-14 Identification of Channelopsin-2 (Chop2) mutations and methods of use
AU2021245195A Active AU2021245195B2 (en) 2012-03-05 2021-10-07 Identification of Channelopsin-2 (Chop2) mutations and methods of use

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2017239601A Active AU2017239601B2 (en) 2012-03-05 2017-10-06 Identification of Channelopsin-2 (Chop2) mutations and methods of use
AU2019216638A Active AU2019216638B2 (en) 2012-03-05 2019-08-14 Identification of Channelopsin-2 (Chop2) mutations and methods of use
AU2021245195A Active AU2021245195B2 (en) 2012-03-05 2021-10-07 Identification of Channelopsin-2 (Chop2) mutations and methods of use

Country Status (16)

Country Link
US (3) US10947281B2 (enExample)
EP (1) EP2822964B1 (enExample)
JP (3) JP6395611B2 (enExample)
KR (1) KR102137717B1 (enExample)
CN (2) CN111378020A (enExample)
AU (4) AU2013230112A1 (enExample)
CA (1) CA2866405A1 (enExample)
DK (1) DK2822964T3 (enExample)
EA (1) EA201491643A1 (enExample)
ES (1) ES2703324T3 (enExample)
HU (1) HUE040487T2 (enExample)
MX (1) MX360085B (enExample)
NZ (1) NZ629843A (enExample)
PL (1) PL2822964T3 (enExample)
PT (1) PT2822964T (enExample)
WO (1) WO2013134295A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470790B2 (en) 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
CN111378020A (zh) 2012-03-05 2020-07-07 韦恩州立大学 通道视蛋白-2(Chop2)突变的鉴定及使用方法
WO2014160281A2 (en) 2013-03-14 2014-10-02 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
US10234761B2 (en) 2013-07-08 2019-03-19 Basf Se Oxime ester photoinitiators
WO2015138616A1 (en) 2014-03-11 2015-09-17 Wayne State University A modified mglur6 promoter and methods of use
KR20230160967A (ko) 2016-05-03 2023-11-24 웨인 스테이트 유니버시티 프로테오좀 억제제를 사용하여 눈에서 바이러스 매개 유전자 전달을 향상시키는 방법
JP2019522469A (ja) * 2016-06-03 2019-08-15 マックス−プランク−ゲゼルシャフト ツア フェルデルンク デア ヴィッセンシャフテン エー．ファウ． チャネルロドプシンの変異型光誘導性イオンチャネル
RU2019109021A (ru) * 2016-08-29 2020-09-29 Уэйн Стейт Юниверсити Идентификация мутаций в вариантах каналопсина, имеющих улучшенную чувствительность к свету, и способы их применения
WO2018106369A2 (en) * 2016-11-06 2018-06-14 Nanoscope Technologies Llc Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
WO2018189247A1 (en) * 2017-04-12 2018-10-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. New optogenetic tool
SG11202004940VA (en) * 2017-12-04 2020-06-29 Salvat Lab Sa Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム
WO2024226667A2 (en) * 2023-04-24 2024-10-31 Nanoscope Therapeutics Inc. Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
EP0977880A2 (en) 1997-04-21 2000-02-09 University Of Florida Materials and methods for treatment of retinal diseases
WO2000015822A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
EP1381276A4 (en) 2001-04-13 2005-02-02 Univ Pennsylvania METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION
WO2003016486A2 (en) 2001-08-16 2003-02-27 Sloan Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
WO2004009022A2 (en) 2002-07-18 2004-01-29 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
JP2007527738A (ja) 2003-11-05 2007-10-04 ニューロヴィジョン， インコーポレイテッド 視覚を改善するための方法および装置
US20070053996A1 (en) 2005-07-22 2007-03-08 Boyden Edward S Light-activated cation channel and uses thereof
US8470790B2 (en) * 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
SI2614079T1 (sl) * 2010-09-08 2015-10-30 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Mutantski kanalnirodopsin 2
CN111378020A (zh) * 2012-03-05 2020-07-07 韦恩州立大学 通道视蛋白-2(Chop2)突变的鉴定及使用方法
KR101639859B1 (ko) * 2014-03-06 2016-07-14 포항공과대학교 산학협력단 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법

Also Published As

Publication number Publication date
HK1205744A1 (en) 2015-12-24
EA201491643A1 (ru) 2015-02-27
HUE040487T2 (hu) 2019-03-28
PL2822964T3 (pl) 2019-05-31
CA2866405A1 (en) 2013-09-12
AU2021245195B2 (en) 2023-09-28
KR102137717B1 (ko) 2020-07-27
JP2019193656A (ja) 2019-11-07
AU2017239601B2 (en) 2019-05-16
NZ727041A (en) 2022-01-28
MX2014010664A (es) 2015-03-06
AU2017239601A1 (en) 2017-10-26
EP2822964B1 (en) 2018-08-22
CN104334575A (zh) 2015-02-04
NZ629843A (en) 2017-03-31
CN111378020A (zh) 2020-07-07
US20150044181A1 (en) 2015-02-12
AU2021245195A1 (en) 2021-11-04
WO2013134295A1 (en) 2013-09-12
US10947281B2 (en) 2021-03-16
DK2822964T3 (en) 2018-12-10
EP2822964A1 (en) 2015-01-14
ES2703324T3 (es) 2019-03-08
US20220033449A1 (en) 2022-02-03
JP2015510759A (ja) 2015-04-13
KR20140132401A (ko) 2014-11-17
MX360085B (es) 2018-10-10
JP6395611B2 (ja) 2018-09-26
JP2018134098A (ja) 2018-08-30
PT2822964T (pt) 2018-11-29
AU2019216638B2 (en) 2021-07-08
US20250066431A1 (en) 2025-02-27
AU2019216638A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
AU2021245195B2 (en) Identification of Channelopsin-2 (Chop2) mutations and methods of use
US20240165198A1 (en) Optogenetic visual restoration using chrimson
JP2009536219A (ja) ロドプシン拡散のインビボ送達による視覚応答の回復
MX2010012592A (es) Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas.
BR112016019432B1 (pt) Composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina
KR20140039281A (ko) 감광성 키메라 gpcr 단백질
US20230159609A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
JP6779546B2 (ja) 視力回復のための多特性オプシンによる光遺伝学的調節及びその別の用途
EP3892738A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
JP7723983B2 (ja) 色認識のための光応答性タンパク質及びその利用
EA043449B1 (ru) ИДЕНТИФИКАЦИЯ МУТАЦИЙ КАНАЛ-ОПСИНА-2 (Chop2) И СПОСОБЫ ПРИМЕНЕНИЯ
HK1205744B (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
NZ727041B2 (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
US20230338581A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted